StockpollyBeta
Get App
Popularity #3,176
VYGR · NASDAQ · Biotechnology

Voyager Therapeutics (VYGR)

Develops CNS gene therapies and antibodies around TRACER delivery and tau biology.

$2.97
vs last close−0.18 (−5.57%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue590203025665131533
Cost of revenue26113230333231363410
Gross profit−218918−2−6−27−25−26−23−1823
835351381210108123230
Research & development262426343036323136362522
8109108910108888
General & administrative8109108910108888
Other expenses−2600−32−30−33−32−31−36−32−10
Operating income−3054−16−15−14−38−35−37−31−30−30−26
435554433322
Interest income335554332222
Other non-operating income0−3−5−3−5−4−4−3−3−3−2−2
Income before tax−2657−11−10−9−34−31−33−28−27−28−24
Income tax expense010001000000
Net income from continuing operations−2656−11−10−9−34−31−33−28−27−28−24
Net income−2656−11−10−9−34−31−33−28−27−28−24
EPS, basic−$0.59$1.28−$0.20−$0.18−$0.16−$0.59−$0.53−$0.57−$0.47−$0.47−$0.47−$0.40
EPS, diluted−$0.59$1.25−$0.20−$0.18−$0.16−$0.59−$0.53−$0.57−$0.47−$0.47−$0.47−$0.40
Weighted average shares, basic444457585858585959595961
Weighted average shares, diluted444557585858585959595961
EBITDA−2959−10−11−8−33−30−32−27−26−27−23
Depreciation & amortization111111111112
EBIT−3057−11−13−9−34−31−33−28−27−28−24